PPP
INO icon

Private Portfolio Partners’s Inovio Pharmaceuticals INO Stock Holding History

Private Portfolio Partners’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,321
Closed -$79.1K – 294
2021
Q4 		$79.1K Buy
+1,321
New +$106K 0.02% 275
2021
Q3 		– Sell
-2,063
Closed -$229K – 262
2021
Q2 		$229K Buy
+2,063
New +$198K 0.07% 235

Other funds holding INO

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Private Portfolio Partners's INO Position: Q1 2022 in Review

Private Portfolio Partners sold out of Inovio Pharmaceuticals (INO) in Q1 2022, closing a stake of 1,321 shares — an estimated $79.1K sold.

Private Portfolio Partners first reported a position in INO in Q2 2021 and held it in 2 quarters. The position peaked at $229K in Q2 2021. 198 funds tracked by Wall St. Rank hold INO as of Q1 2022.

  • Private Portfolio Partners reported no remaining Inovio Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Private Portfolio Partners sold 1,321 Inovio Pharmaceuticals shares in Q1 2022, an estimated $79.1K.
  • Private Portfolio Partners first reported a position in Inovio Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Private Portfolio Partners's Inovio Pharmaceuticals position peaked at $229K in Q2 2021.
  • 198 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2022.

Based on Private Portfolio Partners's 13F filing for Q1 2022, filed 12 May 2022.